These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 21737464)

  • 1. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.
    Haley EC; Thompson JL; Grotta JC; Lyden PD; Hemmen TG; Brown DL; Fanale C; Libman R; Kwiatkowski TG; Llinas RH; Levine SR; Johnston KC; Buchsbaum R; Levy G; Levin B;
    Stroke; 2010 Apr; 41(4):707-11. PubMed ID: 20185783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.
    Bivard A; Garcia-Esperon C; Churilov L; Spratt N; Russell M; Campbell BC; Choi P; Kleinig T; Ma H; Markus H; Molina C; Hsu C; Tsai CH; Meretoja A; Strbian D; Butcher K; Wu T; Davis S; Donnan G; Levi C; Parsons M
    Int J Stroke; 2023 Jul; 18(6):751-756. PubMed ID: 36655938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials.
    Burgos AM; Saver JL
    Stroke; 2019 Aug; 50(8):2156-2162. PubMed ID: 31318627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
    Ramakrishnan TCR; Kumaravelu S; Narayan SK; Buddha SS; Murali C; Majeed PHA; Meenakshi-Sundaram S; Wadia RS; Sharma V; Basu I; Vijaya P; Salam KA; Barmare S; Vaid Z; Nirmal Raj KK; Wattamwar PR; Asokan K; Dhonge V; Nellikunja S; Namjoshi D; Srinivasa R; Laddhad DS; Deshpande SD; Raghunath B; Kalita J; Kumar M; Misra UK; Pradeep M;
    Am J Cardiovasc Drugs; 2018 Oct; 18(5):387-395. PubMed ID: 29948822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
    Parsons M; Spratt N; Bivard A; Campbell B; Chung K; Miteff F; O'Brien B; Bladin C; McElduff P; Allen C; Bateman G; Donnan G; Davis S; Levi C
    N Engl J Med; 2012 Mar; 366(12):1099-107. PubMed ID: 22435369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA).
    Gibson CM; Marble SJ
    Clin Cardiol; 2001 Sep; 24(9):577-84. PubMed ID: 11558838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits.
    Lapchak PA; Araujo DM; Zivin JA
    Exp Neurol; 2004 Jan; 185(1):154-9. PubMed ID: 14697326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenecteplase for Acute Ischemic Stroke Treatment.
    Baird AE; Jackson R; Jin W
    Semin Neurol; 2021 Feb; 41(1):28-38. PubMed ID: 33472268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials.
    Huang X; MacIsaac R; Thompson JL; Levin B; Buchsbaum R; Haley EC; Levi C; Campbell B; Bladin C; Parsons M; Muir KW
    Int J Stroke; 2016 Jul; 11(5):534-43. PubMed ID: 27048693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.
    Kimani PK; Todd S; Stallard N
    Stat Med; 2013 Jul; 32(17):2893-910. PubMed ID: 23413228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials.
    Coutts SB; Berge E; Campbell BC; Muir KW; Parsons MW
    Int J Stroke; 2018 Dec; 13(9):885-892. PubMed ID: 30035698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
    Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
    Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
    Bretz F; Schmidli H; König F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.
    Campbell BCV; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Dowling RJ; Yan B; Bush SJ; Dewey HM; Thijs V; Scroop R; Simpson M; Brooks M; Asadi H; Wu TY; Shah DG; Wijeratne T; Ang T; Miteff F; Levi CR; Rodrigues E; Zhao H; Salvaris P; Garcia-Esperon C; Bailey P; Rice H; de Villiers L; Brown H; Redmond K; Leggett D; Fink JN; Collecutt W; Wong AA; Muller C; Coulthard A; Mitchell K; Clouston J; Mahady K; Field D; Ma H; Phan TG; Chong W; Chandra RV; Slater LA; Krause M; Harrington TJ; Faulder KC; Steinfort BS; Bladin CF; Sharma G; Desmond PM; Parsons MW; Donnan GA; Davis SM;
    N Engl J Med; 2018 Apr; 378(17):1573-1582. PubMed ID: 29694815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience.
    Yeatts SD; Martin RH; Coffey CS; Lyden PD; Foster LD; Woolson RF; Broderick JP; Di Tullio MR; Jungreis CA; Palesch YY;
    Stroke; 2014 May; 45(5):1408-14. PubMed ID: 24699059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-Term Efficacy Outcomes of Tenecteplase versus Alteplase for Acute Ischemic Stroke: A Meta-Analysis of 5 Randomized Trials.
    Requiao LE; Oliveira RS; Reis LS; B Assis AP; G Moreno BN; Cordeiro LR; Solla DF
    Neurol India; 2022; 70(4):1454-1459. PubMed ID: 36076643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
    Coutts SB; Dubuc V; Mandzia J; Kenney C; Demchuk AM; Smith EE; Subramaniam S; Goyal M; Patil S; Menon BK; Barber PA; Dowlatshahi D; Field T; Asdaghi N; Camden MC; Hill MD;
    Stroke; 2015 Mar; 46(3):769-74. PubMed ID: 25677596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.